SCA
CELG

SAC Capital Advisors’s Celgene Corp CELG Stock Holding History

SAC Capital Advisors’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-100,000
Closed -$5.85M – 2129
2013
Q2 		$5.85M Buy
+100,000
New +$6.02M 0.03% 494

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAC Capital Advisors's CELG Position: Q2 2014 in Review

SAC Capital Advisors sold out of Celgene Corp (CELG) in Q2 2014, closing a stake of 142,178 shares — an estimated $9.92M sold.

SAC Capital Advisors first reported a position in CELG in Q2 2013 and held it in 4 quarters. The position peaked at $12.8M in Q3 2013. 995 funds tracked by Wall St. Rank hold CELG as of Q2 2014.

  • SAC Capital Advisors reported no remaining Celgene Corp position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 142,178 Celgene Corp shares in Q2 2014, an estimated $9.92M.
  • SAC Capital Advisors first reported a position in Celgene Corp in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Celgene Corp position peaked at $12.8M in Q3 2013.
  • 995 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.